BridgeBio seesaws after settlement in Pfizer Vyndamax patent dispute (update)
The article reports that BridgeBio Pharma's stock experienced volatility after announcing a settlement with Pfizer regarding patents for Vyndamax (tafamidis). The agreement allows BridgeBio to launch its tafamidis product, acoramidis, in October 2028, or earlier under specific conditions, and includes undisclosed financial terms. This resolution eliminates market uncertainty surrounding the patent dispute.
Biogen Inc (MEX:BIIB) Stock Price, Trades & News
This article provides a detailed stock summary page for Biogen Inc (MEX:BIIB), covering its current stock price, key financial metrics like P/E ratio, market cap, and enterprise value. It also includes an overview of the company's business description as a biopharmaceutical firm focused on neurodegenerative and rare diseases, along with various financial strength, growth, profitability, and valuation ranks. The page highlights warning signs detected by GuruFocus and lists upcoming stock events and recent press releases related to the company.
Pfizer (PFE) Stock Sinks As Market Gains: Here's Why
Pfizer's stock (PFE) fell by 2.47% in the latest trading session, trailing broader market gains. The company's shares have decreased by 6.61% over the past month, underperforming the Medical sector. Analysts project a year-over-year decline in earnings and revenue for Pfizer's upcoming August 4, 2026, earnings release, although its current Zacks Rank is #3 (Hold).
Teladoc Health CAO sells $5,942 in common stock
Teladoc Health's Chief Accounting Officer, Joseph Ronald Catapano, sold 653 shares of company common stock for $5,942 to cover tax withholding obligations associated with RSU vestings. This transaction occurred on July 2, 2026, after 2,083 restricted stock units converted to common stock. Following the sale, Mr. Catapano directly holds 12,267 shares and 10,418 RSUs.
Pfizer's Growth Story Faces a Wait as Pipeline and Leadership Doubts Mount
HSBC analysts downgraded Pfizer (NYSE:PFE) to Hold, lowering their price target due to increased uncertainty surrounding key oncology pipeline assets and recent executive leadership changes. The analysts now believe Pfizer's ambitious high single-digit revenue growth targets for 2028-2032 are unlikely to be validated soon, especially after a Phase 3 setback for sigvotatug vedotin and the expectation of meaningful catalysts for growth programs not arriving until 2027. Investors face a period of waiting for pipeline successes to resolve growth debates, while also dealing with potential impacts from MFN pricing, IRA changes, and loss-of-exclusivity pressures.
Pfizer Trades at Just 8.5x Earnings While Peers Fetch 16x. Is the Discount Justified?
Pfizer is currently trading at a significantly lower earnings multiple (8.5x) compared to its pharmaceutical peers (16.4x), raising questions about whether this discount is justified. The market is weighing Pfizer's pipeline challenges, such as a failed oncology trial, against its strong dividend, rebuilt commercial infrastructure, and future growth projections for 2029 and beyond. The article suggests that proof of pipeline success and reaffirmation of guidance are necessary to validate the company's long-term growth story and reduce the current valuation gap.
Roche pens $490m Astex breast cancer license deal
Roche's subsidiary, Genentech, has signed a global drug discovery and licensing deal with UK biotech Astex Pharmaceuticals for breast cancer drugs. Roche will provide $25 million upfront and potential payments exceeding $465 million based on milestones, along with tiered royalties. This collaboration aims to identify new preclinical candidates for breast cancer treatment, with Genentech leading development and commercialization. The deal highlights Roche's continuing investment in oncology and the growing presence of the UK life sciences sector.
Beam Therapeutics stock hits 52-week high at 36.89 USD
Beam Therapeutics Inc. (BEAM) stock has surged to a new 52-week high of $36.89, currently trading at $37.02, reflecting a 90.88% increase over the past year. This growth is attributed to investor confidence in its genetic medicine approaches and recent positive developments, including FDA clearance for BEAM-304 and promising clinical data from BEAM-302 and BEACON trials. Analysts like H.C. Wainwright have reiterated a "Buy" rating with an $80.00 price target, highlighting the company's progress and strategic initiatives.
Pfizer Inc. stock underperforms Monday when compared to competitors
Pfizer Inc. (PFE) shares dropped 2.47% on Monday, closing at $23.72, despite a generally positive trading session for the broader stock market. The stock finished 17.48% below its 52-week high of $28.75, which was reached on April 2nd. This underperformance occurred as both the S&P 500 Index and the Dow Jones Industrial Average saw gains.
HSBC Drops Pfizer to Hold: Seagen ADC Miss Leaves $43B Bet Without Catalyst
HSBC downgraded Pfizer (NYSE: PFE) from Buy to Hold, cutting its price target to $28, following the failure of sigvotatug vedotin's Phase 3 trial, a key drug from its $43 billion Seagen acquisition. This setback, coupled with executive management changes, has led to a lack of near-term rerating catalysts despite an attractive 7.1% dividend yield. The downgrade highlights increased scrutiny on Pfizer's pipeline development and capital allocation after significant investments.
AstraZeneca PLC Stock (AZN) Moved Down by 3.79% on Jul 6: What Signal Does It Send?
AstraZeneca PLC (AZN) stock decreased by 3.79% on July 6, driven by profit-taking, revised earnings estimates, and regulatory uncertainties despite positive news like a $1.77 billion partnership with CSPC Pharmaceutical and European approval for Enhertu. Analysts have issued downward revisions for 2026 EPS, citing rising R&D costs and pipeline setbacks, including FDA delays for camizestrant and a significant clinical trial failure. The decline reflects a combination of technical overbought conditions and fundamental concerns weighing on investor sentiment.
Price to earnings forward of Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S – TSX:PFE
This page provides financial information for Pfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S, traded on the Toronto Stock Exchange under the ticker PFE. It focuses specifically on the "Price to earnings forward" metric for the company. The market was closed at the time the data was accessed.
Can Alnylam's Drug Pipeline Fuel Its Long-Term Revenue Growth?
Alnylam Pharmaceuticals currently markets four approved drugs, generating significant revenue growth, and expects further top-line boosts from partnerships like Novartis's Leqvio. The company is advancing a promising pipeline with candidates like cemdisiran, zilebesiran, mivelsiran, and nucresiran, which are in various stages of clinical trials and have the potential to expand its commercial portfolio. Despite stiff competition for its lead drug Amvuttra and an expensive stock valuation, Alnylam is focused on long-term growth through its diversified pipeline.
Here Are Monday’s Best Wall Street Analyst Research Calls: Agnico Eagle Mines, Datadog, Delta Air Lines, Gilead Sciences, Okta, Pfizer, Regions Financial, T-Mobile, and More
This article details Wall Street analyst calls for Monday, July 6, 2026, highlighting upgrades for companies like T-Mobile and Gilead Sciences, and downgrades for Datadog and Pfizer. It also covers market movements following a weaker-than-expected jobs report, with gold and cryptocurrencies rising, and Treasury yields mixed. Various companies including Agnico Eagle Mines, Okta, and Glaukos received new coverage initiations.
HSBC Downgrades Pfizer to Hold From Buy, Adjusts Price Target to $28 From $32
HSBC has downgraded Pfizer's stock rating from Buy to Hold and decreased its price target from $32 to $28. This adjustment reflects a revised outlook from the financial institution regarding the pharmaceutical giant's future performance. Pfizer's stock was trading slightly lower in pre-market activity following this news.
This M&T Bank Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Top Wall Street analysts issued downgrades for five major companies on Monday, reflecting a shift in their outlook. Hunter Bancshares, Pfizer, Delta Air Lines, M&T Bank, and Brown & Brown all saw their ratings lowered by various financial institutions, with corresponding adjustments to their price targets. This signals a more cautious stance from these analysts on the future performance of these stocks.
Invivyd (NASDAQ: IVVD) faces 2027 end of PEMGARDA COVID EUA
Invivyd (NASDAQ: IVVD) announced that the FDA has issued a Notice of Termination for the Emergency Use Authorization (EUA) of its COVID-19 monoclonal antibody, PEMGARDA, effective June 29, 2027. This follows the HHS's decision to end the COVID-19 EUA declaration. PEMGARDA will remain authorized during a twelve-month transition period, during which Invivyd plans to discuss potential Biologics License Application (BLA) pathways with the FDA for full approval.
HSBC downgrades Pfizer stock rating on lack of near-term catalysts
HSBC downgraded Pfizer (NYSE:PFE) to Hold from Buy and reduced its price target to $28.00 from $32.00, citing a lack of near-term catalysts and reduced confidence in the potential for a stock rerating. This decision follows a Phase 3 setback in lung cancer trials and recent executive management changes. Despite the downgrade, Pfizer offers an attractive 7.07% dividend yield and is trading only 5% above its 52-week low.
Price to earnings forward of Pfizer Inc. – LS:852009
This article provides financial information for Pfizer Inc. (LS:852009) on TradingView, specifically focusing on its forward price-to-earnings ratio. The content primarily consists of navigation and links within the TradingView platform, indicating where to find financial data and other related analytics for the company.
Novartis to Buy Cancer-Drug Firm Myricx for Up to $1.5 Billion
Novartis AG has agreed to acquire British biotech Myricx Bio for up to $1.5 billion. This acquisition aims to bolster Novartis's cancer drug portfolio with Myricx's experimental therapies that target tumors specifically, minimizing harm to healthy cells. Myricx shareholders are set to receive $1.1 billion upfront, with an additional $400 million in potential milestone payments.
BridgeBio earnings up next: Attruby growth key amid competition
BridgeBio Pharma is set to release its first-quarter earnings, with focus on the commercial performance of its heart drug, Attruby, amidst increasing market competition. Analysts anticipate an improved financial quarter, expecting a loss of 68 cents per share on $178.2 million in revenue, driven by Attruby's launch despite a more competitive landscape and declining EPS estimates. Investors will be closely watching Attruby's market share growth, the company's path to profitability, and pipeline diversification efforts, particularly with upcoming Phase 3 results for encaleret.
Pfizer Inc. (PFE): A Top Dividend Stock to Buy According to Hedge Funds amid Ibrance FDA Milestone
Pfizer Inc. (PFE) is highlighted as a top dividend stock by hedge funds, following the FDA's approval of its drug Ibrance for certain breast cancer patients. This approval expands Ibrance's use to include HR-positive, HER2-positive locally advanced or metastatic breast cancer in combination with trastuzumab after induction treatment. The FDA milestone builds on positive phase 3 study results showing Ibrance reduced disease progression or death by 24% and reinforces Pfizer's leadership in breast cancer treatment.
Merck & Co. outlook and strategy. A closer look at the pharma giant
This article provides an in-depth overview of Merck & Co., a major global pharmaceutical company. It details Merck's business model, strategic focus on oncology and vaccines, financial profile, and research and development pipeline. The company's long-term positioning, competitive landscape, and product portfolio are also discussed for the benefit of long-term oriented investors.
Pfizer Inc. outlines long-term growth strategy as healthcare demand evolves
Pfizer Inc. is focusing on a long-term growth strategy centered on innovative medicines and vaccines, operational efficiency, and a diversified pipeline to meet evolving global healthcare demands. The company leverages its significant scale and broad portfolio across various therapeutic areas, investing heavily in R&D to bring new therapies to market and managing patent expirations by refreshing its product offerings. Pfizer's global footprint, stringent quality control, and cost-efficiency initiatives reinforce its position as a key player in the pharmaceutical sector.
PFE - Pfizer Inc Volatility & Greeks
This article provides key financial data and performance metrics for Pfizer Inc. (PFE). It covers stock volatility, Greeks, trading information, insider ownership, institutional transactions, profitability ratios, and various performance indicators over different timeframes, offering a comprehensive snapshot of the company's financial health and market position.
Pfizer-BioNTech COVID-19 Vaccine from Pfizer Inc. - cornerstone of global mRNA supply
The Pfizer-BioNTech COVID-19 Vaccine remains a key commercial product for Pfizer, driving its shares and serving as an mRNA workhorse for healthcare providers globally. The article details its evolution, manufacturing scale, and impact on Pfizer's broader vaccine and infectious disease strategy, alongside commercial considerations and ongoing safety monitoring. It highlights the vaccine's role in Pfizer's long-term business model, focusing on boosters and leveraging its established mRNA platform.
BMY - Bristol-Myers Squibb Co Volatility & Greeks
This article provides detailed financial and performance data for Bristol-Myers Squibb Co (BMY), including its stock volatility, P/E ratios, dividend yield, and analyst recommendations. It also lists key financial metrics, insider and institutional ownership, and historical price performance over various periods.
Dividend King vs. Growth Giant: Johnson & Johnson Takes on Eli Lilly
Eli Lilly and Johnson & Johnson reported contrasting Q1 2026 results, with Lilly driven by its GLP-1 drugs Mounjaro and Zepbound, showing significant growth, while J&J demonstrated steady growth and extended its dividend streak. Lilly's strategy focuses on metabolic dominance with substantial investments, reflecting a higher forward P/E and aggressive growth. J&J, a Dividend King with lower volatility, prioritizes portfolio diversification, making it a steadier income play.
If You Invested $1,000 in Structure Therapeutics Inc ADR (GPCR)
This article analyzes the historical performance of Structure Therapeutics Inc ADR (GPCR) stock. It details that a $1,000 investment made one year ago would now be worth $2,854, showing a 185.4% total return. The company is a clinical-stage biopharmaceutical firm focusing on oral small molecule treatments for metabolic and cardiopulmonary conditions, leveraging a structure-based drug discovery platform for its pipeline, which includes candidates like Aleniglipron and ACCG-2671.
Pfizer Inc. focuses on its pharmaceutical pipeline as investors watch long-term growth drivers
Pfizer Inc. is actively expanding its portfolio of branded and specialty medicines, with a significant focus on its late-stage pharmaceutical pipeline to drive future revenue and cash flow. The company invests heavily in R&D across various therapeutic areas like oncology, immunology, and rare diseases, while strategically managing patent cycles and market access. Investors are keen on how Pfizer's new launches will offset patent expirations and how its capital allocation supports both growth and shareholder returns.
Moran Wealth Management LLC Purchases 11,862 Shares of EOG Resources, Inc. $EOG
Moran Wealth Management LLC increased its stake in EOG Resources (NYSE:EOG) by 4.1% in the first quarter, purchasing an additional 11,862 shares to bring its total holdings to 301,981 shares valued at $43.7 million. EOG Resources announced strong quarterly results, with EPS of $3.41 topping estimates and revenue up 22.1% year-over-year. The company also declared a quarterly dividend of $1.02 per share, representing an annualized yield of 3.1%, while analysts maintain a "Moderate Buy" rating with an average target price of $155.25.
Merck & Co. focuses on its pharmaceutical pipeline as investors weigh long-term growth
Merck & Co. continues to prioritize its research-driven pharmaceutical pipeline, focusing on oncology, infectious diseases, cardiometabolic disorders, and immunology. The company balances significant R&D investment with shareholder returns, aiming to offset revenue erosion from older products with new therapy launches. Its leading oncology therapy exemplifies its strategy of sustained innovation and clinical development to maintain a competitive market position.
ETFs Investing in Pfizer Inc Shs Cert Deposito Arg Repr 0.25 Shs Stocks
This article lists ETFs that invest in Pfizer Inc Shs Cert Deposito Arg Repr 0.25 Shs stocks. It highlights a specific fund, the CTBC Global High Dividend ETF, outlining its market value, weight, issuer, management style, focus, expense ratio, AUM, price change, and NAV total return over three years. The page provides an overview of how funds can make stock investing more accessible with lower risk.
ETFs Investing in Pfizer Inc Shs Cert Deposito Arg Repr 0.25 Shs Stocks
This article identifies ETFs that include Pfizer Inc Shs Cert Deposito Arg Repr 0.25 Shs (PFEC) stocks, offering investors a more accessible and diversified way to invest in these pharmaceutical shares. It highlights one specific fund, the CTBC Global High Dividend ETF Securities Investment Trust Fund, detailing its market value, weight of PFEC, and other financial metrics. The article suggests ETFs as a means of investing with lower risk and more opportunities.
TEVA - Teva- Pharmaceutical Industries Ltd ADR Latest SEC Filings
This article provides the latest SEC filings information for Teva Pharmaceutical Industries Ltd ADR (TEVA), along with comprehensive financial data, performance metrics, and analyst ratings. It highlights the company's recent stock performance, key financial indicators like market cap and EPS, and insider/institutional ownership details.
Liquidia Corp outlines path in pulmonary hypertension as investors watch regulatory milestones
Liquidia Corp is leveraging its proprietary drug delivery technology to develop therapies for pulmonary hypertension, with a focus on optimizing existing treatments. Investors are closely monitoring regulatory milestones, such as clinical trial data and FDA approvals, and commercialization progress, including market access and funding, which are crucial for the company's long-term growth in this specialized biopharmaceutical sector. The company's stock represents a typical risk-reward profile for a development-stage biotech, with performance tied to regulatory decisions and commercial readiness.
Pfizer Inc. explores new pipelines as investors weigh long-term growth
Pfizer Inc. is focusing on rebuilding its growth momentum by developing a broad pipeline of oncology, immunology, and rare disease candidates, moving past the pandemic vaccine boom. The company is investing heavily in research and development, aiming to offset revenue declines from older products and manage the transition from its Covid-19 related sales. Investors are now evaluating Pfizer's long-term product pipeline and business strategy as it navigates market competition and evolving healthcare regulations.
Mesothelioma Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | GSK, Merck, Bristol-Myers Squibb, AstraZeneca, Roche, Novartis, Pfizer Inc
DelveInsight's "Mesothelioma Pipeline Insight, 2026" report indicates that over 45 key companies are actively developing 50+ Mesothelioma treatment therapies. The report provides a comprehensive assessment of the clinical development scenario, including detailed drug descriptions, mechanisms of action, clinical studies, and regulatory approvals. Emerging therapies from companies like Bristol-Myers Squibb, AstraZeneca, Roche, Novartis, and Pfizer are highlighted, alongside significant clinical trial developments and orphan drug designations for various treatments.
Mesothelioma Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | GSK, Merck, Bristol-Myers Squibb, AstraZeneca, Roche, Novartis, Pfizer Inc
DelveInsight's "Mesothelioma Pipeline Insight, 2026" report provides a comprehensive overview of the global Mesothelioma treatment pipeline, identifying over 45 key companies developing more than 50 therapies. The report details clinical trial progress from pre-clinical to marketed phases, including mechanisms of action, routes of administration, and recent developments like FDA orphan drug designations and trial results for several emerging therapies. Key companies like Bristol-Myers Squibb, AstraZeneca, and Vivace Therapeutics are highlighted for their contributions to the pipeline, which includes immunotherapies, targeted therapies, and CAR-T cell treatments.
H.C. Wainwright Remains a Buy on Biogen (BIIB)
H.C. Wainwright maintained a Buy rating on Biogen (BIIB) with a price target of $237.00. This rating was echoed by Needham's Ami Fadia, while Morgan Stanley holds a Neutral stance. Biogen reported increased quarterly revenue and net profit in its latest earnings release for Q1, ending March 31, 2026.
AT&T Stock Has Held Its Dividend Steady for Four Straight Quarters Reported
AT&T (T) has maintained its quarterly dividend at $0.28 per share for four consecutive quarters, even as its stock price has fallen to near its 52-week low of $20. The company's operating margin rebounded to 23% in Q1 2026, and TIKR's model projects a $36 target price by 2030, suggesting a significant potential return. The stable dividend amidst a lower stock price has increased its yield to 5.4%, making it an attractive option for income-seeking investors.
Pfizer Stock And 2 AI Healthcare Picks Investors May Want To Watch
This article highlights three healthcare stocks – Butterfly Network (BFLY), Pfizer (PFE), and Medtronic (MDT) – that have significant exposure to AI in healthcare. It details each company's operations, market capitalization, and investment considerations, including both opportunities and risks. The piece suggests these companies are compelling options for investors interested in the convergence of inflation-sensitive policy shifts and rapidly advancing AI technology aimed at reducing costs and improving outcomes in the healthcare sector.
Pfizer Stock’s Dividend Yield Sits at 7% Heading Into the Back Half of 2026
Pfizer's stock (PFE) offers a 7% dividend yield as of July 2026, primarily due to a declining share price rather than increased payouts. While Q1 2026 revenue grew 5% year-over-year to $14.45 billion, operating income fell 5% to $4.57 billion, and the quarterly dividend has been flat at $0.43 per share for four consecutive quarters. TIKR's model projects a modest 3% annualized total return for Pfizer stock by 2030, largely driven by the dividend yield rather than significant price appreciation.
Argenx SE outlines growth path in rare disease therapies
Argenx SE, a biotechnology company, is focusing on building a global franchise in autoimmune and rare disease treatments using antibody-based therapies. The company aims to expand its presence in major markets, including the United States, through a blend of internal research and strategic collaborations. Its strategy emphasizes specialized antibody platforms to address hard-to-treat indications, particularly focusing on autoimmune and neuromuscular diseases, with the goal of shifting revenue from milestones to recurring product sales.
Drug Developer Scores Major FDA Nod, Eyes Big Gains in Muscle Disease Market
Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ) has received FDA Fast Track designation for its Duchenne muscular dystrophy treatment, SAT-3247, aiming to accelerate its development. This designation, coupled with existing Orphan Drug and Rare Pediatric Disease designations, positions the company for significant potential in a Duchenne market projected to reach US$62.13 billion by 2030. Analysts have issued "Strong Buy" ratings for Satellos, with price targets ranging from US$11 to US$23, highlighting investor excitement for its ongoing Phase 2 studies.
Novo Nordisk, the maker of Ozempic, is controlled by a Copenhagen charity that holds 77% of the voting power through special shares that have never been traded and legally can never be sold
Novo Nordisk, the pharmaceutical giant behind Ozempic and Wegovy, is uniquely controlled by the Novo Nordisk Foundation, a Copenhagen-based charity. This foundation holds 77% of the voting rights through special A-shares that have never been traded and legally cannot be sold. This unusual structure ensures the company remains Danish, independent, and research-focused, with its substantial dividends directed towards scientific and humanitarian causes globally.
VTRS - Viatris Inc Options
This page provides a detailed financial overview of Viatris Inc. (VTRS), including its key financial metrics, stock performance, insider and institutional ownership, and various valuation ratios. It covers data such as market capitalization, sales, earnings per share, dividend information, and short interest, offering a comprehensive snapshot of the company's current financial health and market position.
Pfizer Paxlovid - antiviral pills that still matter in the US COVID toolkit
Pfizer's Paxlovid remains a crucial oral antiviral treatment for high-risk COVID-19 patients in the US, securing FDA full approval in May 2023 for its effectiveness in reducing severe disease, hospitalization, and death. Despite declining revenue contribution for Pfizer as COVID-related sales normalize, it continues to be a primary tool for clinicians managing high-risk adults. The drug's use requires careful consideration of potential drug interactions, but real-world data consistently support its benefit in preventing severe outcomes even amidst evolving variants and vaccinated populations.
BMY’s Shift Into Russell Value Defensive Indexes Might Change The Case For Investing In Bristol-Myers Squibb (BMY)
Bristol-Myers Squibb (BMY) was reclassified into Russell's Value Defensive and Defensive Indexes in late June 2026, moving out of growth benchmarks. This change could impact how index-linked and style-focused funds hold BMY, potentially shifting its investor base and peer comparisons. While this reclassification mainly affects fund ownership rather than the underlying business, it may heighten focus on BMY's exposure to US drug pricing reforms, particularly Medicare Drug Price Negotiation Program.
Moderna (NASDAQ:MRNA) gains $2.9 billion as investors pile into flu push, beating 2025 revenue
Moderna's stock (NASDAQ:MRNA) surged, adding $2.9 billion in market capitalization, as investor enthusiasm for its flu vaccine candidate, mFlusiva, drove shares up 10.2%. This increase follows FDA advisers' support for the vaccine, with the market cap gain significantly surpassing Moderna's anticipated 2025 revenue. Despite the market uplift, analysts like Citi's Geoff Meacham caution that significant sales from mFlusiva are not expected until late 2027.
